1-20 of 28
Neil Shah, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation

Elias J. Jabbour, MD, Jorge E. Cortes, MD, Moshe Talpaz, MD, Michele Baccarani, MD, Michael J. Mauro, MD, Andreas Hochhaus, MD, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Francois Guilhot, MD, Michael W. Deininger, MD PhD, Neil Shah, MD PhD, Dale L. Bixby, MD, Ian W. Flinn, MD PhD, Thomas O'Hare, PhD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Sergio Santillana, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2016) 128 (22): 3067.
https://doi.org/10.1182/blood.V128.22.3067.3067
Published: 2016
Journal Articles

Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants

Catherine C Smith, MD, Elisabeth Lasater, PhD, Melissa Mccreery, BS, Kimberly Lin, BS, Whitney Stewart, BS, Lauren E Damon, Alexander E Perl, MD, Grace R Jeschke, Mayumi Sugita, MD, Martin Carroll, MD, Scott C. Kogan, MD, Neil Shah, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 141.
https://doi.org/10.1182/blood.V120.21.141.141
Published: 2012
Journal Articles

Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data

Giuseppe Saglio, MD, Hagop M. Kantarjian, MD, Neil Shah, MD, PhD, Elias J. Jabbour, MD, Alfonso Quintas-Cardama, MD, Juan Luis Steegmann, MD, PhD, Concepción Boqué, MD, Charles Chuah, MD, Carolina Pavlovsky, MD, Jiří Mayer, MD, Jon Ukropec, PhD, Mark Wildgust, PhD, Andreas Hochhaus, MD
Journal: Blood
Blood (2012) 120 (21): 1675.
https://doi.org/10.1182/blood.V120.21.1675.1675
Published: 2012
Journal Articles

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Jorge E. Cortes, MD, Dong-Wook Kim, MD, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ron Paquette, MD, PhD, Charles Chuah, MD, Franck E Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J. DeAngelo, MD, PhD, Elisabetta Abruzzese, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, MD, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy Hughes, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M Kantarjian, M.D., The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 163.
https://doi.org/10.1182/blood.V120.21.163.163
Published: 2012
Journal Articles

Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial

Dong-Wook Kim, Jorge E. Cortes, MD, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel DeAngelo, MD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M. Kantarjian, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 3749.
https://doi.org/10.1182/blood.V120.21.3749.3749
Published: 2012
Journal Articles

Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial

Andreas Hochhaus, MD, Dong-Wook Kim, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel DeAngelo, MD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, Martin C Muller, MD, Carlo Gambacorti-Passerini, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 3763.
https://doi.org/10.1182/blood.V120.21.3763.3763
Published: 2012
Journal Articles

Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

Michael W Deininger, MD, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Neil Shah, MD, PhD, Dale Bixby, MD, PhD, Michael J. Mauro, MD, Ian W. Flinn, MD, PhD, Thomas O'Hare, PhD, Simin Hu, PhD, David J. Dorer, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Brian J. Druker, Moshe Talpaz, MD
Journal: Blood
Blood (2012) 120 (21): 3743.
https://doi.org/10.1182/blood.V120.21.3743.3743
Published: 2012
Journal Articles

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Michael J. Mauro, MD, Jorge E. Cortes, MD, Dong-Wook Kim, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, MD, FACP, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, David J. Dorer, Ronald Keith Knickerbocker, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy Hughes, MD, MBBS, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M. Kantarjian, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 3747.
https://doi.org/10.1182/blood.V120.21.3747.3747
Published: 2012
Journal Articles

Clinical Impact of an Internet-Based Tool to Help Guide Therapeutic Changes While Monitoring Patients with Chronic Myeloid Leukemia Receiving First-Line Tyrosine Kinase Inhibitor Therapy

Kevin L. Obholz, PhD, Daniel J. DeAngelo, MD, PhD, Michael J. Mauro, MD, Neil Shah, MD, PhD, B. Douglas Smith, MD, Andrew Bowser, ELS, CCMEP, Eric D. Peterson, EdM, FACEHP, Jerald P. Radich, MD
Journal: Blood
Blood (2012) 120 (21): 4279.
https://doi.org/10.1182/blood.V120.21.4279.4279
Published: 2012
Journal Articles

Competitive Allele Specific TaqMan® PCR (castPCR™) Technology for Sensitive Detection of AC220-Resistant FLT3 Kinase Domain Mutations in Primary AML Patient Samples.

Willard Cheng, BS, Elisabeth Lasater, PhD, Catherine C Smith, MD, Mouanoutoua Mokang, Yun Bao, PhD, Neil Shah, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 2559.
https://doi.org/10.1182/blood.V120.21.2559.2559
Published: 2012
Journal Articles

Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220

Catherine C Smith, MD, Jason Chin, PhD, Elisabeth Lasater, PhD, Amy L. Paguirigan, PhD, Kimberly Lin, BS, Whitney Stewart, BS, Sara Salerno, BS, Lauren E Damon, Mark J. Levis, MD, PhD, Alexander E Perl, MD, Kevin Travers, PhD, Andrew Kasarskis, PhD, Jerald P. Radich, MD, Neil Shah, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 674.
https://doi.org/10.1182/blood.V120.21.674.674
Published: 2012
Journal Articles

Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

Hagop M. Kantarjian, MD, Dong-Wook Kim, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel DeAngelo, MD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John Goldman, DM, FRCP, FRCPath, FMedSci, Neil Shah, MD, PhD, Jorge E. Cortes, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 915.
https://doi.org/10.1182/blood.V120.21.915.915
Published: 2012
Journal Articles

Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects the Evolution of Polyclonal and Compound BCR-ABL Mutations in Patients Who Relapse On Kinase Inhibitor Therapy

Catherine C Smith, MD, Michael Brown, PhD, Wendy T Parker, PhD, Kimberly Lin, BS, Kevin Travers, PhD, Susana Wang, Susan Branford, PhD, Neil Shah, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 917.
https://doi.org/10.1182/blood.V120.21.917.917
Published: 2012
Journal Articles

Novel Chromosomal Rearrangements and Sequence Mutations in High-Risk Ph-Like Acute Lymphoblastic Leukemia

Kathryn G. Roberts, PhD, Ryan D Morin, M.Sc., Jinghui Zhang, PhD, Martin Hirst, Ph.D., Richard C. Harvey, PhD, Corynn Kasap, BS, Xiang Chen, PhD, Michael Edmonson, Ph.D., I-Ming Chen, DVM, MS, Neil Shah, MD, PhD, Meenakshi Devidas, PhD, Gregory H. Reaman, MD, Malcolm A. Smith, MD, PhD, Ching-Hon Pui, MD, James R. Downing, MD, Daniela S Gerhard, Ph.D., Cheryl L Willman, MD, Mignon L Loh, MD, Stephen P Hunger, MD, Marco A. Marra, PhD, Charles G Mullighan, MBBS, MD, FRACP, FRCPA, MSc
Journal: Blood
Blood (2011) 118 (21): 67.
https://doi.org/10.1182/blood.V118.21.67.67
Published: 2011
Journal Articles

Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutants

Catherine C. Smith, MD, Lauren E. Damon, Xiaotian Zhu, PhD, Sara Salerno, BS, Neil Shah, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 930.
https://doi.org/10.1182/blood.V118.21.930.930
Published: 2011
Journal Articles

Validation of FLT3-ITD As a Therapeutic Target in Human Acute Myeloid Leukemia

Catherine C. Smith, MD, Jason Chin, PhD, Qi Wang, PhD, Sara Salerno, BS, Lauren E. Damon, Jeremy P. Hunt, Mark J. Levis, MD, PhD, Alexander E Perl, MD, Kevin Travers, PhD, Susana Wang, Andrew Kasarskis, PhD, Eric Schadt, PhD, John Kuriyan, PhD, Neil Shah, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 937.
https://doi.org/10.1182/blood.V118.21.937.937
Published: 2011
Journal Articles

Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies

Jorge E. Cortes, Hagop M. Kantarjian, Neil Shah, MD, PhD, Dale Bixby, MD, PhD, Michael J. Mauro, MD, Ian W. Flinn, MD, PhD, Thomas O'Hare, Simin Hu, PhD, Tim Clackson, PhD, Victor M. Rivera, PhD, Christopher D. Turner, MD, FAAP, Frank Haluska, MD, PhD, Brian J. Druker, Michael W. Deininger, Moshe Talpaz, MD
Journal: Blood
Blood (2011) 118 (21): 602.
https://doi.org/10.1182/blood.V118.21.602.602
Published: 2011
Journal Articles

BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia

Christian Hurtz, Katerina Hatzi, PhD, Leandro Cerchietti, MD, Eugene Park, Yong-Mi Kim, MD, MPH, PhD, Parham Ramezani-Rad, Hassan Jumaa, PhD, Martin C Muller, Wolf-Karsten Hofmann, MD, Andreas Hochhaus, MD, Anupriya Agarwal, PhD, Neil Shah, MD, PhD, Ari Melnick, MD, Brian J. Druker, Markus Muschen
Journal: Blood
Blood (2011) 118 (21): 446.
https://doi.org/10.1182/blood.V118.21.446.446
Published: 2011
Journal Articles

Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations

Warren Fiskus, BSc, PhD, Catherine C. Smith, MD, Jacqueline Smith, MS, Scott C. Wise, MS, Elisabeth Lasater, PhD, Lauren E. Damon, Sara Salerno, BS, Allan Fleming, MD, Ruben Reyes, MD, Siddhartha Ganguly, MD, Mark S. Berger, MD, Tom J. Rutkoski, Ph.D, Joseph McGuirk, DO, Neil Shah, MD, PhD, Kapil N. Bhalla, MD
Journal: Blood
Blood (2011) 118 (21): 2611.
https://doi.org/10.1182/blood.V118.21.2611.2611
Published: 2011
Journal Articles

Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects Polyclonal and Compound BCR-ABL in Patients Who Relapse on Kinase Inhibitor Therapy,

Catherine C. Smith, MD, Michael Brown, PhD, Jason Chin, PhD, Corynn Kasap, BS, Sara Salerno, BS, Lauren E. Damon, Kevin Travers, PhD, Susana Wang, Andrew Kasarskis, PhD, Eric Schadt, PhD, Neil Shah, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3752.
https://doi.org/10.1182/blood.V118.21.3752.3752
Published: 2011